Promising New Antibiotic Defies Conventional Wisdom on Treating Superbug. UVA’s Dr. Paul S. Hoffman says, “It’s one step in the right direction (into solving antibiotic resistance).”
The University of Virginia’s new findings challenge conventional wisdom on the best way to develop new treatments for Clostridium difficile. Clostridium difficile is a growing problem in healthcare settings nationwide. UVA’s drug, Amixicile in early testing suggests it could be more effective than existing options.